Comparison of patient characteristics
| Variable . | MSD/MUD; n = 75 . | Haplo; n = 70 (%) . |
|---|---|---|
| Median patient age, years (range) | 49 (22-64) | 41 (2-64) |
| Age <18, n (%) | 0 (0) | 14 (20) |
| Pre-BMT disease status, n (%) | ||
| CR | 45 (60) | 34 (49) |
| MRD | 14 (19) | 11 (16) |
| Active disease | 16 (21) | 25 (35) |
| HCT-CI, median (range) | 2 (0-8) | 1 (0-5) |
| 0-3, n (%) | 49 (66) | 64 (91) |
| ≥3, n (%) | 16 (21) | 6 (9) |
| Median donor age: years (range) | 41 (17-67) | 38 (11-69) |
| Female → Male, n (%) | 20 (27) | 24 (34) |
| Recipient CMV positive, n (%) | 39 (53) | 28 (40) |
| CMV mismatch, n (%) | 34 (45) | 23 (33) |
| Cell dose infused, n (range) | ||
| TNC x 108/kg | 3.8 (0.32-8.82) | 4.8 (2.63-11.2) |
| CD34+ cells × 106/kg | 3.3 (1-9.87) | 4.5 (1.77-11.24) |
| CD3+ cells × 107/kg | 4.2 (1.5-30.28) | 4.78 (1.09-11.7) |
| Variable . | MSD/MUD; n = 75 . | Haplo; n = 70 (%) . |
|---|---|---|
| Median patient age, years (range) | 49 (22-64) | 41 (2-64) |
| Age <18, n (%) | 0 (0) | 14 (20) |
| Pre-BMT disease status, n (%) | ||
| CR | 45 (60) | 34 (49) |
| MRD | 14 (19) | 11 (16) |
| Active disease | 16 (21) | 25 (35) |
| HCT-CI, median (range) | 2 (0-8) | 1 (0-5) |
| 0-3, n (%) | 49 (66) | 64 (91) |
| ≥3, n (%) | 16 (21) | 6 (9) |
| Median donor age: years (range) | 41 (17-67) | 38 (11-69) |
| Female → Male, n (%) | 20 (27) | 24 (34) |
| Recipient CMV positive, n (%) | 39 (53) | 28 (40) |
| CMV mismatch, n (%) | 34 (45) | 23 (33) |
| Cell dose infused, n (range) | ||
| TNC x 108/kg | 3.8 (0.32-8.82) | 4.8 (2.63-11.2) |
| CD34+ cells × 106/kg | 3.3 (1-9.87) | 4.5 (1.77-11.24) |
| CD3+ cells × 107/kg | 4.2 (1.5-30.28) | 4.78 (1.09-11.7) |
CMV, cytomegalovirus; CR, complete remission; haplo-HLA, haploidentical donor; HCT-CI, Hematopoietic Cell Transplantation-Comorbidity Index; MRD, minimal residual disease; MSD-HLA, matched sibling donor; MUD-HLA, matched unrelated donor; TNC, total nucleated cells.